SCHEMBL3386669

SCHEMBL3386669

O=C(CC(O)C(=O)O)OC(C(=O)O)C(O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
MMP9 P14780 1/20 0.47
MMP13 P45452 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
TET2 Q6N021 6/20 0.39
TET3 O43151 2/20 0.39
TET1 Q8NFU7 1/20 0.39
SRC P12931 1/20 0.36
TSHR P16473 2/20 0.36
OR51E2 Q9H255 1/20 0.36
PGK1 P00558 1/20 0.32
PGK2 P07205 1/20 0.32
KDM4A O75164 2/20 0.32
KDM4C Q9H3R0 2/20 0.32
KDM2A Q9Y2K7 2/20 0.32
PGD P52209 1/20 0.31
CYP2C9 P11712 1/20 0.30
PDE4A P27815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27542310 0.96 MMP1 (0.44) MMP1MMP2MMP3MMP9MMP13
SCHEMBL28275674 0.89 MMP1 (0.52) MMP1MMP2MMP3MMP9MMP13
SCHEMBL2845135 0.88 MMP1 (0.44) MMP1MMP2MMP3MMP9MMP13
Malic Acid SCHEMBL27687431 0.82 SMN1; SMN2 (0.50) MMP1MMP2MMP3MMP9MMP13
SCHEMBL1168152 0.80 MMP1 (0.42) MMP1MMP2MMP3MMP9MMP13
SCHEMBL11574916 0.80 MMP1 (0.44) MMP1MMP2MMP3MMP9MMP13
SCHEMBL23630284 0.78 TSHR (0.41) MMP1MMP2MMP3MMP9MMP13
SCHEMBL11574927 0.77 MMP1 (0.42) MMP1MMP2MMP3MMP9MMP13
SCHEMBL9006278 0.77 MMP1 (0.39) MMP1MMP2MMP3MMP9MMP13
SCHEMBL7118530 0.77 MMP1 (0.39) MMP1MMP2MMP3MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220016020-A1 SKIN DULLNESS SUPPRESSING AGENT, AND SKIN BARRIER FUNCTION MAINTAINING OR IMPROVING AGENT EZAKI GLICO CO., LTD. (JP) 2022-01-20 US claimed
JP-59033364-A None JP disclosed
US-12037334-B2 Inhibitors of VAP-1 ACUCELA INC. (US) 2024-07-16 US disclosed
EP-4392521-A1 HOME CARE COMPOSITIONS Colgate-Palmolive Company (US) 2024-07-03 EP disclosed
WO-2024130110-A1 HOME CARE COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2024-06-20 WO disclosed
US-20240165098-A1 OPHTHALMIC COMPOSITION Sydnexis, Inc. 2024-05-23 US disclosed
US-20240139166-A1 OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA Sydnexis, Inc. 2024-05-02 US disclosed
US-20240091367-A1 ORALLY DISINTEGRATING PALATABLE FORMULATIONS OF DROTAVERINE AND METHOD OF PREPARATION THEREOF SUSHMA PAUL BERLIA (IN) 2024-03-21 US disclosed
WO-2024033786-A1 METHOD FOR TRIETHYLENETETRAMINE PURIFICATION PHILERA NEW ZEALAND LTD. (NZ) 2024-02-15 WO disclosed
US-11896588-B2 Ophthalmic composition Sydnexis, Inc. (US) 2024-02-13 US disclosed
WO-1999032436-A1 INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed
WO-1998016192-A1 GERMICIDAL COMPOSITION ALTERNA, INC. (US) 1998-04-23 WO disclosed
US-5670344-A Preventing undesired color formation in iron fortified chocolate-flavored beverages by including edible acids or their salts THE PROCTER & GAMBLE COMPANY (US) 1997-09-23 US disclosed
WO-1997027758-A1 IRON FORTIFIED CHOCOLATE-FLAVORED BEVERAGES INCLUDING EDIBLE ACIDS OR THEIR SALTS THE PROCTER & GAMBLE COMPANY (US) 1997-08-07 WO disclosed
EP-0182210-B1 CEPHALOSPORIN DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1991-02-27 EP disclosed
US-4742053-A ANTIBIOTICS BANYU PHARMACEUTICAL CO., LTD. (JP) 1988-05-03 US disclosed
US-4677100-A ANTIBIOTICS BANYU PHARMACEUTICAL CO., LTD. (JP) 1987-06-30 US disclosed
EP-0182210-A2 Cephalosporin derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1986-05-28 EP disclosed
JP-S5933364-A PREPARATION OF MICA-BASE PEARLESCENT PIGMENT SANYO SHIKISO KK 1984-02-23 JP disclosed
US-4009173-A Butyrophenone derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11896588-B2 Ophthalmic composition MYOC, PDE6H, PDE6C MMP1 426/4885MMP2 1921/4885MMP3 279/4885
US-20240139166-A1 OPHTHALMIC COMPOSITIONS FOR PRESBYOPIA CRYZ, CRYAB, AQP3 MMP1 3333/4885MMP2 3914/4885MMP3 2042/4885
US-12037334-B2 Inhibitors of VAP-1 VAPB, VAPA, TOE1 MMP1 373/4885MMP2 148/4885MMP3 114/4885
US-20240165098-A1 OPHTHALMIC COMPOSITION MYOC, PDE6H, PDE6C MMP1 426/4885MMP2 1921/4885MMP3 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.